158 related articles for article (PubMed ID: 11748582)
1. Molecular markers and determinants of prostate cancer metastasis.
Gopalkrishnan RV; Kang DC; Fisher PB
J Cell Physiol; 2001 Dec; 189(3):245-56. PubMed ID: 11748582
[TBL] [Abstract][Full Text] [Related]
2. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer metastasis-suppressor genes: a current perspective.
Yoshida BA; Chekmareva MA; Wharam JF; Kadkhodaian M; Stadler WM; Boyer A; Watabe K; Nelson JB; Rinker-Schaeffer CW
In Vivo; 1998; 12(1):49-58. PubMed ID: 9575426
[TBL] [Abstract][Full Text] [Related]
4. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer.
Kasper S; Smith JA
J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729
[TBL] [Abstract][Full Text] [Related]
5. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
6. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
7. The role of motility proteins and metastasis-suppressor genes in prostate cancer progression.
Rinker-Schaeffer CW; Chekmareva MA; Mohler JL
Stem Cells; 1996 Sep; 14(5):508-16. PubMed ID: 8888492
[TBL] [Abstract][Full Text] [Related]
8. Autochthonous mouse models for prostate cancer: past, present and future.
Huss WJ; Maddison LA; Greenberg NM
Semin Cancer Biol; 2001 Jun; 11(3):245-60. PubMed ID: 11407949
[TBL] [Abstract][Full Text] [Related]
9. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
10. Molecular methods for predicting the metastatic potential of prostate cancer.
Schalken JA
Cancer Surv; 1991; 11():43-54. PubMed ID: 1726788
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
12. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort.
Mucci LA; Pawitan Y; Demichelis F; Fall K; Stark JR; Adami HO; Andersson SO; Andrén O; Eisenstein AS; Holmberg L; Huang W; Kantoff PW; Perner S; Stampfer MJ; Johansson JE; Rubin MA
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):249-51. PubMed ID: 18199732
[TBL] [Abstract][Full Text] [Related]
13. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
Kauffman EC; Robinson VL; Stadler WM; Sokoloff MH; Rinker-Schaeffer CW
J Urol; 2003 Mar; 169(3):1122-33. PubMed ID: 12576866
[TBL] [Abstract][Full Text] [Related]
14. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
15. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
16. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
17. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents.
Khamis ZI; Iczkowski KA; Sang QX
Med Res Rev; 2012 Sep; 32(5):1026-77. PubMed ID: 22886631
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
19. The Drg-1 gene suppresses tumor metastasis in prostate cancer.
Bandyopadhyay S; Pai SK; Gross SC; Hirota S; Hosobe S; Miura K; Saito K; Commes T; Hayashi S; Watabe M; Watabe K
Cancer Res; 2003 Apr; 63(8):1731-6. PubMed ID: 12702552
[TBL] [Abstract][Full Text] [Related]
20. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
